| Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma TM Habermann, EA Weller, VA Morrison, RD Gascoyne, PA Cassileth, ... Journal of clinical oncology 24 (19), 3121-3127, 2006 | 1639 | 2006 |
| Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma M Attal, V Lauwers-Cances, C Hulin, X Leleu, D Caillot, M Escoffre, ... New England Journal of Medicine 376 (14), 1311-1320, 2017 | 1230 | 2017 |
| Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma PG Richardson, RL Schlossman, E Weller, T Hideshima, C Mitsiades, ... Blood, The Journal of the American Society of Hematology 100 (9), 3063-3067, 2002 | 1039 | 2002 |
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, ... Blood, The Journal of the American Society of Hematology 116 (5), 679-686, 2010 | 1030 | 2010 |
| BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression AM Roccaro, A Sacco, P Maiso, AK Azab, YT Tai, M Reagan, F Azab, ... J Clin Invest, 2013 | 836 | 2013 |
| A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma PG Richardson, E Blood, CS Mitsiades, S Jagannath, SR Zeldenrust, ... Blood 108 (10), 3458-3464, 2006 | 645 | 2006 |
| Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results … P Armand, A Nagler, EA Weller, SM Devine, DE Avigan, YB Chen, ... J Clin Oncol 31 (33), 4199-206, 2013 | 553 | 2013 |
| Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu YT Tai, M Dillon, W Song, M Leiba, XF Li, P Burger, AI Lee, K Podar, ... Blood, The Journal of the American Society of Hematology 112 (4), 1329-1337, 2008 | 540 | 2008 |
| Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors AK Ng, MVP Bernardo, E Weller, K Backstrand, B Silver, KC Marcus, ... Blood, The Journal of the American Society of Hematology 100 (6), 1989-1996, 2002 | 514 | 2002 |
| Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger AK Ng, MP Bernardo, E Weller, KH Backstrand, B Silver, KC Marcus, ... Journal of Clinical Oncology 20 (8), 2101-2108, 2002 | 465 | 2002 |
| Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484 SJ Horning, E Weller, KM Kim, JD Earle, MJ O'Connell, TM Habermann, ... Journal of Clinical Oncology 22 (15), 3032-3038, 2004 | 459 | 2004 |
| Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the … D de Jong, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, ... Journal of Clinical Oncology 25 (7), 805-812, 2007 | 456 | 2007 |
| Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study JN Winter, EA Weller, SJ Horning, M Krajewska, D Variakojis, ... Blood 107 (11), 4207-4213, 2006 | 365 | 2006 |
| Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy PG Richardson, W Xie, C Mitsiades, AA Chanan-Khan, S Lonial, ... Journal of Clinical Oncology 27 (21), 3518, 2009 | 338 | 2009 |
| Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III … H Hochster, E Weller, RD Gascoyne, TM Habermann, LI Gordon, T Ryan, ... Journal of Clinical Oncology 27 (10), 1607, 2009 | 326 | 2009 |
| Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease S Vallet, S Mukherjee, N Vaghela, T Hideshima, M Fulciniti, S Pozzi, ... Proceedings of the National Academy of Sciences 107 (11), 5124-5129, 2010 | 306 | 2010 |
| Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years—United States, July–December 2021 LD Zambrano MMWR. Morbidity and mortality weekly report 71, 2022 | 284 | 2022 |
| The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow … B Lin, K Podar, D Gupta, YT Tai, S Li, E Weller, T Hideshima, S Lentzsch, ... Cancer research 62 (17), 5019-5026, 2002 | 267 | 2002 |
| Prognostic role of circulating exosomal miRNAs in multiple myeloma S Manier, CJ Liu, H Avet-Loiseau, J Park, J Shi, F Campigotto, KZ Salem, ... Blood, The Journal of the American Society of Hematology 129 (17), 2429-2436, 2017 | 262 | 2017 |
| Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma J Rosenblatt, B Vasir, L Uhl, S Blotta, C MacNamara, P Somaiya, Z Wu, ... Blood, The Journal of the American Society of Hematology 117 (2), 393-402, 2011 | 259 | 2011 |
Irene GhobrialDana-Farber Cancer InstituteVerified email at dfci.harvard.edu
